U
TVRD

UBS’s Tvardi Therapeutics TVRD Stock Holding History

UBS’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$19K Sell
63
-164
-72% -$67.3K ﹤0.01% 8088
2014
Q2 		$139K Buy
+227
New +$122K ﹤0.01% 5569

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS's TVRD Position: Q3 2014 in Review

UBS reduced its Tvardi Therapeutics (TVRD) stake by 72% in Q3 2014, selling an estimated $67.3K and leaving 63 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #8088.

UBS first reported a position in TVRD in Q2 2014 and has held it in 2 quarters since. The position peaked at $139K in Q2 2014. 56 funds tracked by Wall St. Rank hold TVRD as of Q3 2014.

  • UBS held 63 shares of Tvardi Therapeutics worth $19K as of Q3 2014.
  • UBS sold 164 Tvardi Therapeutics shares in Q3 2014, an estimated $67.3K.
  • Tvardi Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8088 holding.
  • UBS first reported a position in Tvardi Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • UBS's Tvardi Therapeutics position peaked at $139K in Q2 2014.
  • 56 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.